{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:58:40Z","timestamp":1768478320299,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Heparin-induced thrombocytopenia (HIT) involves platelet activation and aggregation caused by heparin or HIT antibodies associated with poor survival outcomes. We report a case of HIT that occurred after hemodialysis was started for rapidly progressive glomerulonephritis (RPGN), which was caused by anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), and ultimately resulted in asymptomatic cerebral infarction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 76-year-old Japanese man was urgently admitted to our hospital for weight loss and acute kidney injury (serum creatinine: 12\u00a0mg\/dL). Hemodialysis therapy was started using heparin for anticoagulation. Blood testing revealed elevated titers of myeloperoxidase anti-neutrophil cytoplasmic antibodies, and renal biopsy revealed crescentic glomerulonephritis with broad hyalinization of most of the glomeruli and a pauci-immune staining pattern. These findings fulfilled the diagnostic criteria for microscopic polyangiitis, and the patient was diagnosed with RPGN caused by AAV. Steroid pulse therapy, intermittent pulse intravenous cyclophosphamide, and oral steroid therapy failed to improve the patient\u2019s renal function, and maintenance dialysis was started. However, on day 15, his platelet count had decreased to 47,000\/\u00b5L, with clotting observed in the hemodialysis catheter. Magnetic resonance imaging of the head identified acute asymptomatic brain infarction in the left occipital lobe, and a positive HIT antibody test result supported a diagnosis of type II HIT. During hemodialysis, the anticoagulant treatment was changed from heparin to argatroban. Platelet counts subsequently normalized, and the patient was discharged. A negative HIT antibody test result was observed on day 622.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There have been several similar reports of AAV and HIT co-existence. However, this is a rare case report on cerebral infarction with AAV and HIT co-existence. Autoimmune diseases are considered risk factors for HIT, and AAV may overlap with other systemic autoimmune diseases. To confirm the relationship between these two diseases, it is necessary to accumulate more information from future cases with AAV and HIT co-existence. If acute thrombocytopenia and clotting events are observed when heparin is used as an anticoagulant, type II HIT should always be considered in any patient due to its potentially fatal thrombotic complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02433-8","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T19:02:47Z","timestamp":1623697367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Yoshitaka","family":"Furuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"2433_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0272-6386(96)90134-1","volume":"28","author":"S Yamamoto","year":"1996","unstructured":"Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Dis. 1996;28:82\u20135.","journal-title":"Am J Dis"},{"key":"2433_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.ki.5002631","volume":"73","author":"M Carrier","year":"2008","unstructured":"Carrier M, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, et al. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int. 2008;73:213\u20139.","journal-title":"Kidney Int"},{"key":"2433_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1046\/j.1538-7836.2003.00270.x","volume":"1","author":"BH Chong","year":"2003","unstructured":"Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1:1471\u20138.","journal-title":"J Thromb Haemost"},{"key":"2433_CR4","first-page":"53","volume":"58","author":"BH Chong","year":"1989","unstructured":"Chong BH, Berndt MC. Heparin-induced thrombocytopenia. Br J Haematol. 1989;58:53\u20137.","journal-title":"Br J Haematol"},{"key":"2433_CR5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0735-1097(98)00134-X","volume":"31","author":"DB Brieger","year":"1998","unstructured":"Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449\u201359.","journal-title":"J Am Coll Cardiol"},{"key":"2433_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMcp052967","volume":"355","author":"GM Arepally","year":"2006","unstructured":"Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809\u201317.","journal-title":"N Engl J Med"},{"key":"2433_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/bmj.285.6342.606","volume":"285","author":"DJ Davies","year":"1982","unstructured":"Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J (Clin Res Ed). 1982;285:606.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2433_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendation for conducting studies and\/or clinical trials in systemic vasculitis focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605\u201317.","journal-title":"Ann Rheum Dis"},{"key":"2433_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/archinte.164.4.361","volume":"164","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361\u20139.","journal-title":"Arch Intern Med"},{"key":"2433_CR10","first-page":"938","volume":"62","author":"BM Alexander","year":"2005","unstructured":"Alexander BM, Daniel CB, Julien B. Posterior cerebral artery infarction from middle cerebral artery infarction. Arch Neurol. 2005;62:938\u201341.","journal-title":"Arch Neurol"},{"key":"2433_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/j.ajkd.2009.03.012","volume":"54","author":"A Davenport","year":"2009","unstructured":"Davenport A. Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis. 2009;54:361\u201374.","journal-title":"Am J Kidney Dis"},{"key":"2433_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","volume":"4","author":"GK Lo","year":"2006","unstructured":"Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4T\u2019s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759\u201365.","journal-title":"J Thromb Haemost"},{"key":"2433_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/asheducation-2011.1.143","volume":"2011","author":"TE Warkentin","year":"2011","unstructured":"Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program Book. 2011;2011:143\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program Book"},{"key":"2433_CR14","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.thromres.2013.01.005","volume":"131","author":"K Althaus","year":"2013","unstructured":"Althaus K, Hron G, Strobel U, Abbate R, Rogolino A, Davidson S, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res. 2013;131:e85\u201390.","journal-title":"Thromb Res"},{"key":"2433_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3109\/s10165-008-0107-3","volume":"18","author":"K Nagai","year":"2008","unstructured":"Nagai K, Kotani T, Takeuchi T, Shoda T, Hata-Kobayashi A, Wakura D, et al. Successful treatment of thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangiitis. Mod Rheumatol. 2008;18:643\u20136.","journal-title":"Mod Rheumatol"},{"key":"2433_CR16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838\u201343.","journal-title":"Circulation"},{"key":"2433_CR17","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286\u201392.","journal-title":"N Engl J Med"},{"key":"2433_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/1076029606298996","volume":"13","author":"T Matsuo","year":"2007","unstructured":"Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost. 2007;13:182\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"key":"2433_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000094959","volume":"104","author":"V Hartman","year":"2006","unstructured":"Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P. Pseudo-pulmonary embolism as sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract. 2006;104:143\u20138.","journal-title":"Nephron Clin Pract"},{"key":"2433_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1592\/phco.25.4.615.61036","volume":"25","author":"DL DeEugenio","year":"2005","unstructured":"DeEugenio DL, Ruggiero NJ, Thomson LJ, Menajovsky LB, Herman JH. Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval. case report and review of the literature. Pharmacotherapy. 2005;25:615\u20139.","journal-title":"Pharmacotherapy"},{"key":"2433_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.transci.2013.01.007","volume":"49","author":"M Schell","year":"2013","unstructured":"Schell M, Petras M, Szczepiorkowski ZM, Ornstein DL. Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy. Transfus Apher Sci. 2013;49:185\u20138.","journal-title":"Transfus Apher Sci"},{"key":"2433_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","volume":"12","author":"TE Warkentin","year":"2019","unstructured":"Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12:685\u201398.","journal-title":"Expert Rev Hematol"},{"key":"2433_CR23","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1182\/blood-2008-08-173062","volume":"113","author":"A Greinacher","year":"2009","unstructured":"Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4\/heparin immune response. Blood. 2009;113:4970\u20136.","journal-title":"Blood"},{"key":"2433_CR24","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1182\/blood-2008-10-186064","volume":"113","author":"TE Warkentin","year":"2009","unstructured":"Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009;113:4963\u20139.","journal-title":"Blood"},{"key":"2433_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.2011.08746.x","volume":"154","author":"S Kato","year":"2011","unstructured":"Kato S, Takahashi K, Ayabe K, Samad R, Fukaya E, Friendmann P, et al. Heparin-induced thrombocytopenia: analysis of risk factor in medical in-patients. Br J Haematol. 2011;154:373\u20137.","journal-title":"Br J Haematol"},{"key":"2433_CR26","first-page":"13","volume":"117","author":"B Klinkhammer","year":"2018","unstructured":"Klinkhammer B, Gruchalla M. Is there an association between heparin-induced thrombocytopenia (HIT) and autoimmune disease? WMJ. 2018;117:13\u20137.","journal-title":"WMJ"},{"key":"2433_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.autrev.2016.03.011","volume":"15","author":"Z Cai","year":"2016","unstructured":"Cai Z, Zhu Z, Greene MI, Cines DB. Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT). Autoimmun Rev. 2016;15:752\u20135.","journal-title":"Autoimmun Rev"},{"key":"2433_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/ar1184","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther. 2004;6:107\u201311.","journal-title":"Arthritis Res Ther"},{"key":"2433_CR29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","volume":"67","author":"BS Salter","year":"2016","unstructured":"Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol. 2016;67:2519\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"2433_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10067-018-4212-1","volume":"38","author":"E Mart\u00edn-Nares","year":"2019","unstructured":"Mart\u00edn-Nares E, Zu\u00f1iga-Tamayo D, Hinojosa-Azaola A. Prevalence of overlap of antineutrophil cytoplasmic antibody associated vasculitis with systemic autoimmune diseases: an unrecognized example of poliautoimmunity. Clin Rheumatol. 2019;38:97\u2013106.","journal-title":"Clin Rheumatol"},{"key":"2433_CR31","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1093\/ndt\/13.12.3226","volume":"13","author":"SD Roe","year":"1998","unstructured":"Roe SD, Cassidy MJ, Haynes AP, Byrne JL. Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. Nephrol Dial Transplant. 1998;13:3226\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2433_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4009\/jsdt.42.453","volume":"42","author":"K Kaneda","year":"2009","unstructured":"Kaneda K, Fukunaga N, Kudou A, Ohno E, Imagawa Y, Ohishi K, et al. Heparin-induced thrombocytopenia (HIT) in an acute uremic patient with ANCA-associated glomerulonephritis. Nihon Toseki Igakkai Zasshi. 2009;42:453\u20138.","journal-title":"Nihon Toseki Igakkai Zasshi"},{"key":"2433_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2169\/internalmedicine.50.4939","volume":"50","author":"S Mandai","year":"2011","unstructured":"Mandai S, Nagahama K, Tsuura Y, Hirai T, Yoshioka W, Takahashi D, et al. Recovery of renal function in a dialysis-dependent patient with microscopic polyangiitis and both myeloperoxidase anti-neutrophil cytoplasmic antibodies and anti-glomerular basement membrane antibodies. Intern Med. 2011;50:1599\u2013603.","journal-title":"Intern Med"},{"key":"2433_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ckj\/sft075","volume":"6","author":"KM Thong","year":"2013","unstructured":"Thong KM, Toth P, Khwaja A. Management of heparin-induced thrombocytopenia (HIT) in patients with systemic vasculitis and pulmonary haemorrhage. Clin Kidney J. 2013;6:622\u20135.","journal-title":"Clin Kidney J"},{"key":"2433_CR35","first-page":"2724304","volume":"2019","author":"T Nonaka","year":"2019","unstructured":"Nonaka T, Harada M, Sumi M, Ishii W, Ichikawa T, Kobayashi M. A case of heparin-induced thrombocytopenia that developed in the therapeutic course of anti-neutrophil cytoplasmic antibody-associated vasculitis. Case Rep Rheumatol. 2019;2019:2724304.","journal-title":"Case Rep Rheumatol"},{"key":"2433_CR36","doi-asserted-by":"crossref","unstructured":"Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:340S-80S.","DOI":"10.1378\/chest.08-0677"},{"key":"2433_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3899\/jrheum.170896","volume":"46","author":"A Kang","year":"2019","unstructured":"Kang A, Antonelou M, Wong NL, Tanna A, Arulkumaran N, Tam FWK, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2019;46:285\u201393.","journal-title":"J Rheumatol"},{"key":"2433_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/rheumatology\/ken035","volume":"47","author":"PM Stassen","year":"2008","unstructured":"Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology. 2008;47:530\u20134.","journal-title":"Rheumatology"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02433-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T19:03:19Z","timestamp":1623697399000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02433-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2433"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02433-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"31 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}